Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Fineline Cube May 27, 2026
Company Deals

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Fineline Cube May 27, 2026
Company Deals

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Fineline Cube May 27, 2026
Company Deals

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Fineline Cube May 27, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Fineline Cube May 27, 2026
Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Drug

GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU

Fineline Cube Jan 21, 2025

UK-based GSK plc (NYSE: GSK, LON: GSK) has announced receiving approval from the European Commission...

Company Drug

Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving another clearance from the...

Company Deals

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets

Fineline Cube Jan 21, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...

Company Drug

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2320 in AML

Fineline Cube Jan 21, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the first subject dosing in an...

Company Deals

Danaher Partners with Huashan Hospital to Develop Alzheimer’s Diagnostic Solutions

Fineline Cube Jan 21, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced a partnership between...

Company Drug

Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA

Fineline Cube Jan 21, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...

Company Deals

Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health

Fineline Cube Jan 21, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation...

Policy / Regulatory

NHSA Outlines 2025 Work Plan and 2024 Medical Insurance Status

Fineline Cube Jan 20, 2025

The National Healthcare Security Administration (NHSA) last week held a press conference, addressing questions regarding...

Company Drug

FDA Approves AstraZeneca’s Calquence for Mantle Cell Lymphoma

Fineline Cube Jan 20, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) last week revealed that the US Food and...

Company Deals Medical Device

NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business

Fineline Cube Jan 20, 2025

US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device...

Company Drug

MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis

Fineline Cube Jan 20, 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...

Policy / Regulatory

Tianjin Healthcare Official Gao Xue Under Investigation

Fineline Cube Jan 20, 2025

Gao Xue, director of the National High-value Medical Consumables Joint Procurement Office, member of the...

Medical Device Policy / Regulatory

US BIS Imposes Export Controls on Biotech Lab Instruments

Fineline Cube Jan 20, 2025

The Department of Commerce’s Bureau of Industry and Security (BIS) of the United States last...

Company

Junshi Biosciences Forecasts 29.71% Revenue Growth for 2024

Fineline Cube Jan 20, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has released its 2024 annual...

Company Drug

FDA Clears Amgen’s Lumakras and Vectibix Combo for KRAS G12C-mutated mCRC

Fineline Cube Jan 20, 2025

US-based Amgen (NASDAQ: AMGN) has announced receiving clearance from the US Food and Drug Administration...

Company Drug

Luye Pharma Launches Erzofri in US Market

Fineline Cube Jan 20, 2025

China-based Luye Pharma Group (HKG: 2186) has announced the initiation of commercialization of its in-house...

Company Drug

Novo Nordisk’s Semaglutide 7.2 mg Shows Superior Weight Loss in Phase III Study

Fineline Cube Jan 20, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III...

Company Deals

Xinzeyuan Medical Raises Series B+ Funding for Surgical Supply Chain

Fineline Cube Jan 20, 2025

Xinzeyuan Medical Technology Co., Ltd, a minimally invasive surgical supply chain platform enterprise based in...

Company Drug

Zai Lab’s KarXT NDA Accepted by NMPA for Schizophrenia Treatment

Fineline Cube Jan 20, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that a New Drug...

Company Drug

Frontier Biotechnologies Gains NMPA Approval for Albuvirtide Phase II Study

Fineline Cube Jan 20, 2025

Nanjing-based Frontier Biotechnologies Inc. has announced receiving approval from the National Medical Products Administration (NMPA)...

Posts pagination

1 … 230 231 232 … 672

Recent updates

  • Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing
  • TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC
  • Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech
  • Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Company Drug

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.